-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.
-
Summary
-
ZyVersa Therapeutics, Inc. annual/quarterly Deferred Federal Income Tax Expense (Benefit) history and growth rate for Q4 2022.
- ZyVersa Therapeutics, Inc. Deferred Federal Income Tax Expense (Benefit) for the quarter ending December 31, 2022 was -$152K.
- ZyVersa Therapeutics, Inc. annual Deferred Federal Income Tax Expense (Benefit) for 2023 was -$19.1M, a 772% decline from 2022.
Deferred Federal Income Tax Expense (Benefit), Quarterly (USD)